ACS CAN Supports FDA’s Marketing Denial Order of Logic Technology Development

November 15, 2022

Washington, D,C. – The American Cancer Society Cancer Action Network (ACS CAN) and its partners submitted an amicus curiae (or friend-of-the-court) brief today in support of the U.S. Food and Drug Administration’s marketing denial order (MDO) for Logic Technology Development’s menthol flavored e-cigarettes. Logic’s menthol e-cigarette is the first menthol-flavored e-cigarette product the FDA has ruled on.

The following is a statement from Lisa Lacasse, president of ACS CAN:

“The FDA was doing its job when it issued the MDO to Logic requiring it to remove its menthol-flavored e-cigarettes from the market. There is extensive evidence that the tobacco industry has used and continues to use menthol flavoring to target youth, the LGBTQ+ community and Black Americans. Menthol makes it easier to initiate tobacco use, and harder to quit, so should not be permitted on the market. While we await the FDA’s final rule to eliminate menthol cigarettes, it’s critical to stop the sale of all flavored tobacco products including menthol. Eliminating menthol and other flavors in all products will maximize the public health impact by preventing the industry from luring children into a lifetime of addiction. ACS CAN urges the court to uphold FDA’s MDO of Logic’s products, as they endanger the public health.”

Media Contacts

Emily Burr
Director, Media Advocacy
Washington, D.C.